Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen KYPROLIS (carfilzomib by Year
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide volume growth YoY (%) (%)
Amgen KYPROLIS (carfilzomib: 12.0% in FY2023, down 2.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“KYPROLIS ® (carfilzomib) sales increased 8% year-over-year for the fourth quarter and 13% for the full year, driven by 8% and 12% volume growth, respectively.”
Source: Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Reported in Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide volume growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 12.0% | -2.0 pts | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 14.0% | +10.0 pts | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 4.0% | – | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
Cite this data
StockData. (2026). Amgen KYPROLIS (carfilzomib (%), annual FY2021–FY2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-kyprolis-vol
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.